Navigation Links
Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
Date:11/1/2008

Phase I Clinical Data and Additional Preclinical Results for Non-Nucleoside

HCV Polymerase Inhibitor Being Presented at AASLD

SAN DIEGO, Nov. 1 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today the results of a Phase I clinical trial of ANA598 in healthy volunteers and additional preclinical data that support ANA598 as one of the leading non-nucleoside polymerase inhibitors currently in development for the treatment of HCV. These results are being presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) being held in San Francisco, California, from October 31 - November 4. ANA598 is the Company's investigational hepatitis C non- nucleoside polymerase inhibitor.

ANA598 Phase I Study Results

In the Phase I study in healthy volunteers, ANA598 was administered as capsules at single oral doses of 400 mg, 800 mg, 1400 mg, 2000 mg (fed and fasted) and 3000 mg. In addition, a separate cohort received two 800 mg doses 12 hours apart. ANA598 was well tolerated at all doses and there were no serious adverse events or withdrawals from the study, although definitive conclusions regarding product safety and tolerability cannot be made until the results of future clinical trials of longer duration in more patients are known. All reported adverse events were classified as mild or moderate, with no apparent dose relationship and no pattern of events within any body system. The pharmacokinetic profile demonstrated sustained plasma levels of ANA598 with a half-life of 24 to 30 hours in the fasted state and 22 hours in the fed state, consistent with the potential for once-daily or twice-daily oral dosing. In the cohort that received two 800 mg
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
2. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
3. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
6. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
9. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
10. Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura
11. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... Although colonoscopy exams prevent many colon cancer ... method for detecting colorectal cancers 2 , the procedure ... . EndoChoice ® Inc. today unveiled research that ... accuracy of this procedure and greatly reduces the number ... these clinical trial results and featuring the Fuse system ...
(Date:5/17/2013)... , May 17, 2013  Lakeland Industries, Inc. ... of protective clothing for industry, healthcare and to first ... release its financial results for the fiscal 2013 fourth ... May 21, 2013 at stock market close and will ... 4:30 p.m. eastern. (Logo: http://photos.prnewswire.com/prnh/20120611/NY21959LOGO ...
(Date:5/17/2013)... -- Sony Biotechnology Inc. ("Sony") today announced the launch of the ... chip.  Sony will also be exhibiting its newly rebranded reagent ... the EC800 flow cytometer, and new SP6800 Spectral Analyzer will ... be held at the San Diego ... from May 20 - 22.  The 8-well ...
Breaking Medicine Technology:New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 2New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 3Lakeland Industries to Report Fiscal Fourth Quarter and Year End Financial Results and Conduct Conference Call 2Sony Delivers New Technology for Science to CYTO 2013 2
... , NEW YORK ... Kantar Health , a leading healthcare-focused consultancy and ... in tracking and evaluating pharmaceutical promotion on the prescribing behavior ... and Regimens, a timely, robust tool to assess oncology drug ...
... , PRINCETON, N.J. , Feb. 2 ... the Company), a late-stage biotechnology company, announced today the publication ... of Vaccine, which describes preclinical formulations of RiVax™, ... authored by the Company,s collaborators at the University of ...
Cached Medicine Technology:Kantar Health and ImpactRx Launch CancerMPact Monthly Drugs and Regimens for Oncology Business Decisions 2Kantar Health and ImpactRx Launch CancerMPact Monthly Drugs and Regimens for Oncology Business Decisions 3Kantar Health and ImpactRx Launch CancerMPact Monthly Drugs and Regimens for Oncology Business Decisions 4Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin 2Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin 3Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin 4Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin 5Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin 6Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin 7
(Date:5/19/2013)... Healthcare leaders will gather at the ... Walt Disney World Swan and Dolphin in Orlando, Fla., ... care delivery and healthcare reform and implementation. , “Reform ... markets, with consolidation, efficiency and reduced payments ... Ebert, Amerinet president and CEO. “There is a real ...
(Date:5/19/2013)... New York (PRWEB) May 19, 2013 ... in a federal litigation now underway in U.S. District ... Case Management Order dated May 3rd, the Court has ... Nominee Pool to eight cases rather than four. The ... scheduled for Thursday, May 23rd. (In re: Actos Product ...
(Date:5/19/2013)... According to a new market ... (2013 – 2018): By Applications (Healthcare (Endoscopy, Radiology, ... CMOS, Contact IS, Infrared, X-Ray) And Geography" published ... was $8.00 billion in 2012 and is expected ... estimated CAGR of 3.84% from 2013 to 2018. ...
(Date:5/19/2013)... May 19, 2013 Fat Burning Furnace ... program that provides people with fat burning diet ... order this Fat Burning Furnace package, people will receive ... they can download quickly. The Fat Burning Furnace manual ... people build lean muscle mass. In addition, this book ...
(Date:5/19/2013)... Dr. Keith Chertok now provides gum disease ... gums and increase the chance of a healthier smile. ... Procedure (LANAP) not only removes diseased gum tissue in patients, ... bone for dental implants. , LANAP uses a ... can also help stimulate the healthy tissue as well as ...
Breaking Medicine News(10 mins):Health News:Healthcare Leaders Gather at 2013 Amerinet Member Conference to Share New Ways to Reduce Costs and Enhance Care Delivery 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3Health News:Fat Burning Diet | How “Fat Burning Furnace” Helps People Lose Their Weight Naturally And Fast – V-kool 2Health News:Berkeley, CA Periodontist, Dr. Keith Chertok Now Treats Gum Disease Patients With Laser Gum Surgery Prior to Placing Dental Implants 2
... ... ... Golding is an avid cyclist and a man with a dream. His dream was ... programmer, it seemed Mr. Golding,s dream would never stand a chance competing with a multitude ...
... What,s the most effective way to convince young women to ... their risk of melanoma, the deadliest form of skin cancer, ... wrinkled skin. "They,re not worried about skin cancer, ... said June Robinson, a professor of dermatology at Northwestern University ...
... and inner-ear disorders, and Johns Hopkins University,s provost and ... the Prosper Mnire Society,s 2010 gold medal. The ... basis of Mnire,s disease, named for the French scientist ... "constant ringing noise in the head," or so-called tinnitus, ...
... difference, but others call this risky , MONDAY, May 17 ... not spread beyond the gland doesn,t make much difference in ... , "One thing that really surprised me was how good ... report on the study, published in the May issue of ...
... drugs in euthanasia and in cases without explicit ... according to a study in CMAJ ... . Euthanasia is legal in Belgium if ... care, one of which is that they discuss ...
... ... Records and Health Information Exchange , ... McHenry County, IL (Vocus) May 17, 2010 -- Centegra ... a health information technology sharing program that creates the region’s first-ever Health Information Exchange ...
Cached Medicine News:Health News:Former Microsoft Employee Combines Passion For Technology With American Made Chris King Bicycle Parts 2Health News:Former Microsoft Employee Combines Passion For Technology With American Made Chris King Bicycle Parts 3Health News:Wrinkles are scarier than skin cancer for young tanners 2Health News:Wrinkles are scarier than skin cancer for young tanners 3Health News:Johns Hopkins provost honored with international award 2Health News:Experts Divided on Whether to Treat Thyroid Cancer 2Health News:Experts Divided on Whether to Treat Thyroid Cancer 3Health News:The role of nurses in physician-assisted dying 2Health News:Centegra Health System Launches New Physician Network 2Health News:Centegra Health System Launches New Physician Network 3
... aspirator is intended for destruction and removal ... operative interventions in the field of a ... In an operational zone in a consequence ... with liquid environment interaction arises cavitational processes. ...
... Dissectron ultrasonic aspirator, portable ... surgical aspirator for the ... tissue available only outside ... in a very compact ...
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Deflected large type, opening width 7.0 mm and length 7.5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Deflected large type, opening width 7.0 mm and length 7.5 mm....
Medicine Products: